ThromboGenics to Change Name to Oxurion

June 29, 2018: By Jon Swedien

ThromboGenics intends to change its name to “Oxurion,” the Belgium company announced June 27.

Shareholders will be asked to approve the move July 27.

The change would take effect Sept. 10 and alter the company’s stock ticker symbol from “THR” to “OXUR.”

Oxurion is derived from the words oxygen and Orion, a Greek mythological figure who had his sight restored after being blinded, ThromboGenics said.

ThromboGenics is focused on back of the eye diseases, with a pipeline in diabetic eye disease. The company owns the global rights to Jetrea (ocriplasmin), which is approved for symptomatic vitreomacular adhesion in the US and vitreomacular traction outside the US. The company’s clinical pipeline includes:

–THR-317, a PlGF inhibitor, which is in an ongoing Phase III study in combination Lucentis for the treatment of diabetic macular edema (DME).

–THR-149, a plasma kallikrein inhibitor, which is in a Phase I clinical study for DME.

–THR-687, an integrin antagonist, which is in preclinical development for the treatment of diabetic retinopathy and DME. It is expected to enter the clinic in mid-2018.

Need Deeper Analysis? Sign up for Market Scope's monthly newsletter to get in-depth coverage of the ophthalmic market, including quarterly procedure volumes based on survey data and meeting coverage from around the world.

Recent Ophthalmic News

China’s Innovent Plans $500 Million IPO on Hong Kong Exchange

FDA Accepts Bausch + Lomb’s NDA Filing for Loteprednol Etabonate Ophthalmic Gel

Allergan Launches Refresh Repair Lubricant Eye Drops

US Federal Trade Commission Approves Takeda’s Bid for Shire

Nikon to Acquire Ophthalmic Distributor Chuo Sangio to Merge with Optos Subsidiary

Wills Eye Hospital to Use $5 Million Gift to Support Expansion

Pixium Vision’s PRIMA Implanted in Five Patients with Atrophic Dry AMD

Iuvo BioScience Acquires Oculos Clinical Research

Alcon Will Be Worth $20 Billion to $30 Billion After Spinoff, Novartis Chairman Says

Katena Acquires Blink Medical, Adding to String of Recent Purchases

Opthea’s Phase IIb Trial for Wet AMD Candidate Reaches Midway Point for Enrollment

Ocugen Starts Phase III Trial of OCU300 for Ocular Graft Versus Host Disease

Oculocare Medical Receives US FDA 510(k) Approval for ALLEYE, an Amsler Grid App

Santen Ventures Invests $1 Million in Qura’s QSmart System

Elsalys Biotech Says New Studies Confirm Anti-CD160 Potential in Ophthalmology

Eyedaptic Presents Augmented Reality Glasses for AMD at OCTANe Summit

Quantel Medical Launches Vitra 2 Photocoagulator

Novartis Announces Plans to Spin Off Alcon

Glaukos Announces FDA Approval of iStent Inject for Lowering IOP

Aerpio Prices $45M Public Offering, Moves to Nasdaq Capital Market

Coming soon

2018 Glaucoma Device Report: A Global Market Analysis for 2017 to 2023